Genelux and Newsoara Announce Collaboration and License Agreement for Oncolytic Immunotherapies

Genelux Corporation | September 29, 2021

Genelux Corporation, a clinical-stage immunotherapy company, and Newsoara BioPharma Co., Ltd., announced a collaboration and exclusive license for the development and commercialization of Olvi-Vec and other oncolytic viruses.

According to the terms of the agreement, Newsoara shall have exclusive rights in Greater China (mainland China, Hong Kong, Macau and Taiwan) to Olvi-Vec for which Genelux currently is planning a U.S. based Phase 3 registration trial in platinum resistant/refractory ovarian cancer. Newsoara also shall have exclusive rights in Greater China to Genelux's proprietary oncolytic virus platform, and the parties will collaborate on the development of novel oncolytic immunotherapeutics.

Newsoara, at its cost and expense, will be responsible for development and commercialization and will have the future right to manufacture licensed products in Greater China. The parties also will collaborate on a Phase 2 clinical trial for the intravenous delivery of Olvi-Vec in a new indication using clinical sites in China and the U.S. Newsoara will be responsible for all trial costs.

Under terms of the agreement, Genelux will receive up-front and near-term payments totaling $11 million and will be eligible to receive additional per-product payments of up to $160.5 million, contingent on certain development, regulatory and commercial milestones, plus tiered royalties on net sales ranging from mid-single-digit to mid-double-digit percentages. Genelux shall have an exclusive license outside of Greater China to oncolytic virus products derived by Newsoara and will pay Newsoara milestones and royalties on sales of any such products which Genelux elects to develop.

We are delighted to be working with Newsoara on developing Olvi-Vec, as well as on our broader collaboration. It is a dynamic organization with a commitment to advancing cutting-edge therapeutics, whose strength in research, development and manufacturing in China is a perfect complement to our focus on the discovery and clinical development of novel virotherapies. Together we look forward to accelerating the development of Olvi-Vec and to strengthening and broadening our pipeline of next-generation oncolytic viral immunotherapies.

- Thomas Zindrick, J.D., President and CEO of Genelux.

About Olvimulogene Nanivacirepvec (Olvi-Vec)
Olvi-Vec is a proprietary, non-pathogenic oncolytic vaccinia virus, modified to increase its safety, tumor selectivity and therapeutic potential. Virus-mediated oncolysis results in immunogenic cell death and triggers immune activation and memory for long-term immunotherapy against cancer. Olvi-Vec has been administered to more than 150 patients in clinical studies. In these studies, Olvi-Vec was generally well tolerated and the data provided evidence of clinical benefit.

About Newsoara
Newsoara is a clinical-stage biopharmaceutical company with the mission to develop and commercialize life changing medicines for the treatment of patients with cancer, autoimmune, metabolic and other major diseases in China and around the world. With fully integrated drug discovery, CMC and clinical development capabilities, Newsoara has built a robust and broad pipeline for treating major diseases with unmet needs. Newsoara has assembled a world-class management team with extensive experience in novel drug development that is motivated to improve and impact human health worldwide.

About Genelux Corporation
Genelux is a clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company's most advanced product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus (VACV), a stable DNA virus with a large engineering capacity. The core of Genelux's discovery and development efforts revolves around the company's proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec.


Scientists have used biology to create technology for thousands of years have become really good at it. However, sometimes it feels like the promise of bio-based fuels, materials, and medicines have fallen flat.My research is re-imagining how we tinker with biology, how we might "think outside the cell"! Breaking open bacteria and using their parts to do chemistry allows us to design, build, and test  biotechnologies in a fraction of the time it would take in living bacteria. Now we can imagine a world where all of our material items were made from biology!

Other News

Biotimize Announces the Opening of a Fundraising Round to Build the First Biological CDMO in Brazil

Biotimize | September 06, 2022

Biotimize, a functional growth-stage biotechnology as a service company with a mission to transform lives through biotechnology, today announced the opening of a $30 million Series A fundraising round. The investment will enable Biotimize to build the first biological CDMO in Brazil and to become the first end-to-end biological CDMO in South America. Brazilian universities, startups, and medium-large companies face enormous challenges in developing biological Active Pharmaceutical Ingredients. These difficulties are evidenced by the low number of biopharmaceutical products launched through 100% Brazilian research, a sub-optimal biological manufacturing capacity the low number of facilities with an active GMP certification, and the very high cost of importing biological products. Among many causes, this has occurred chiefly due to the absence of any Brazilian biological CDMOs, despite the existence of more than 500 worldwide. Recent efforts have sought to change the historically discouraging biopharmaceutical scenario in Brazil. The Brazilian government has legislated several industrial incentives and the Brazilian Health Regulatory Agency is also enforcing strict adherence to the ICH guidelines. “The impact of building the CDMO goes far beyond the financials. Biotimize will help build the foundation for a growing scientific community that currently has no structure for development or GMP production,” says Fernando Barbosa, CEO of Biotimize. A 32,000 square-foot parcel of land was donated to Biotimize by the City of Piracicaba, and Biotimize is negotiating partnerships with world renowned equipment suppliers, centers of API characterization and GMP training organizations. “The CDMO will have independent upstream suites for mammalian cell cultures focused on recombinant protein production, like monoclonal antibodies. This is especially important for a country with over 200 million inhabitants and a large potential market for biosimilars,” adds Fernando. About Biotimize Biotimize is a Biotechnology as a Service company led by entrepreneurs with solid experience in innovation, acquired in different companies and research centers around the world. With a mission to transform lives through biotechnology, Biotimize enables ideas, treatments, and dreams to become reality. Biotimize is on its way to being the first biological CDMO in Brazil.

Read More


Biocytogen Announces Collaboration with FineImmune to Develop TCR-Mimic Antibody-Based Cell Therapy

Biocytogen | September 16, 2022

Biocytogen Pharmaceuticals Co., Ltd. announced a strategic collaboration with Guangzhou FineImmune Biotechnology Co., LTD. to co-develop cell-based therapeutic drugs targeting intracellular tumor-associated antigens. Biocytogen will use its proprietary TCR-mimic antibody platform to discover fully human antibody sequences that will be further developed using FineImmune’s unique cell therapy platform. Biocytogen’s TCR-mimic antibody development platform utilizes its proprietary fully human antibody RenMiceTM that have been further engineered to express a human leukocyte antigen gene. Antibodies against intracellular tumor-associated antigens are subjected to advanced high-throughput antibody screening technologies to discover antibodies with high specificity and affinity. “Most tumor antigens are intracellular, and our TCR-mimic platform provides a solution for developing antibodies against these valuable targets. TCR-mimic antibodies generated by our TCR-mimic platform have potentials to be developed into multiple drug modalities such as T cell engagers, bispecific/multispecific antibodies and CAR-T therapies. We are pleased to collaborate with FineImmune to explore the application of our antibodies in the field of cell therapies.” Dr. Yuelei Shen, Founder, Chairman and CEO of Biocytogen FineImmune is a pioneering T cell therapy company, and has solved multiple critical barriers in the microenvironment of solid tumors by using multiple proprietary technology platforms, such as GSOP for T-cell engineering, HAP for TCR identification, CMP for personalized TCR-T cell production and in vivo T-cell delivery platform (TDP). FineImmune’s product pipelines include TCR-T, CAR-T, TAL, TIL, etc. The company developed the first personalized neoantigen-specific TCR-T cell therapy, which is in phase I clinical trial now. In addition, FineImmune possesses technologies for the precision prediction of the efficacy and side effects of immunotherapy, enabling healthcare professionals to provide effective and safe immunotherapy to patients with common malignant tumors. “T cells play an important role in treating cancers. Biocytogen’s advanced TCR-mimic platform makes it possible for us to develop T cell therapies against crucial but low-expressed intracellular tumor antigens,” said Dr. Penghui Zhou, Founder and Chief Technology Officer of FineImmune. “We focus on providing efficient and safe immunotherapy using advanced technologies. This collaboration will promote the development of new cell therapeutic drugs and the expansion of the potential of immunotherapy to benefit patients.” About the TCR-Mimic Platform Biocytogen’s T Cell Receptor Mimic platform utilizes HLA-expressing fully human antibody mice to generate antibodies to intracellular tumor-associated antigens when immunized with MHC-antigen-peptide complexes. Subsequently, Biocytogen’s high-throughput antibody screening platform aims to swiftly identify TCR-mimic antibodies with higher specificity and affinity than endogenous TCRs derived from patients. Currently, antibody sequences against multiple intracellular targets have been obtained, and their efficacies have been verified in vitro and in vivo. Fully human antibody sequences obtained from the TCR-mimic platform can empower the development of T cell engagers, bispecific/multispecific antibodies, and CAR-T therapies. About Biocytogen Biocytogen Pharmaceuticals Co., Ltd. is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMabTM /RenLite® mice platforms for fully human monoclonal and bispecific antibody development, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop antibody drugs for more than 1000 targets, known as Project Integrum, and has entered ongoing collaborations with dozens of partners worldwide to produce a variety of first-in-class and/or best-in-class antibody drugs. The company's pipeline includes 12 core products, among which two products are in phase II multi-regional clinical trials and two products are in phase I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany. On September 1, 2022, Biocytogen was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 02315.HK. About FineImmune Guangzhou FineImmune Biotechnology Co., Ltd. is an innovation driven company based in China. The company is mainly engaged in the development of solid tumor immunotherapy drugs and related businesses. It has solved key technical bottlenecks in solid tumor immunotherapy and possesses core technologies. A number of T-cell therapy products for solid tumors are in clinical trials, as well as diagnostic reagents for accurate identification of effective populations. It has a 2000 square meter immunotherapy R&D laboratory and a GMP production workshop for cell therapy products in Guangzhou Science City. The company's individualized TCR-T cell therapy product (new drug) has been carried out clinical research in the Affiliated Tumor Hospital of Sun Yat sen University. At present, more than 20 immune cell therapy products and technologies are under research and development.

Read More


Delfi Diagnostics Selected as the Liquid Biopsy Partner for 4-IN-THE-LUNG-RUN: A Large-Scale European Lung Cancer Screening Study

Delfi Diagnostics | September 12, 2022

Delfi Diagnostics, a pioneering developer of a new class of high-performance, accessible liquid biopsy tests for early cancer detection and monitoring, has been selected as the liquid lung cancer biopsy partner in Europe's multi-national, randomized, prospective lung cancer screening trial known as 4-IN-THE-LUNG-RUN, or 4ITLR. Through 4ITLR, European investigators are studying how often – every year, or every other year – individuals should get screened if their initial CT scan is negative. Delfi's technology is paired to the study objectives by measuring whether Delfi can identify individuals in Europe's screen-eligible population who are most likely to benefit from a CT scan. The collaboration, initiated and facilitated through a partnership between the Netherlands Cancer Institute ((NKI), with Dr. D. van den Broek as PI) and the institute for DiagNostic Accuracy (iDNA), includes Delfi analyzing the first 9,000 subjects enrolled through the trial in the Netherlands and France (Gustave Roussy) - generating data that can support Delfi's research and subsequent implementation within the European Union. "One of the goals of our study is to examine how a liquid biopsy test might improve screening in a manner that is cost-effective. We are eager to explore how a low-cost liquid biopsy platform could help us screen more high-risk Europeans." prof. Matthijs Oudkerk, MD, PhD, Chief Scientific Officer at iDNA and leading the Radiology and AI readings of 4ITLR Based on the results of the NELSON trial, the European Union is expected to initiate a European lung cancer screening program for individuals at risk due to their smoking and age. "We know that LDCT screening is effective in reducing lung cancer mortality," said Peter B. Bach, Delfi Diagnostics Chief Medical Officer. "This study should lay the groundwork for widespread, cost efficient screening of those at risk in Europe. Delfi is honored to be part of it." Lung cancer kills more than 380,000 Europeans each year, and more than half of all new lung cancer diagnoses in Europe occur at stage IV, when 5-year survival rates can be as low as 2 percent. But screening older heavy smokers with low-dose CT could save up to 80,000 lives in Europe per year. About Delfi Diagnostics Delfi is developing a new class of liquid biopsy tests for early detection based on altered genome-wide fragmentation profiles, also known as "fragmentomes," representing aberrant packaging of DNA in cancer cells. By applying advanced machine learning algorithms, these fragment patterns are detectable at a very low sequencing cost. Delfi is using this technology to develop highly sensitive and specific cancer detection assays intended for wide and cost-effective distribution and adoption. About The Netherlands Cancer Institute (NKI) and CVV The NKI is among the world's foremost comprehensive cancer centers, combining innovative fundamental, translational, and clinical research with dedicated patient care. Our research institute gratefully acknowledges funding from the Dutch Ministry of Health, Welfare and Sport, the Dutch Cancer Society, and individual donors. The NKI Center for Early Diagnostics is an initiative of the NKI. Our Center combines innovation and scientific research to provide certainty in an early stage for risk factors or signs that may indicate cancer. About iDNA iDNA is a Contract Research Organization specialized in early-stage lung cancer, and researching new technologies for the early detection and treatment of lung cancer, with comorbidities in cardiovascular diseases and COPD/emphysema. Key to the early detection of lung cancer are high quality lung cancer screening programs and therefore iDNA wants to set the ''golden standard'' for worldwide lung cancer screening. iDNA works with relevant, early-stage, asymptomatic, high- to medium-risk lung cancer (sub)populations, up to a large, multi-national scale. In addition, iDNA provides several services facilitating the required validation of liquid- and imaging biomarkers and/or therapeutics, while working with KOLs and research partners worldwide. iDNA thereby provides leading pharmaceutical, biotech and AI partners with the opportunity to implement their disruptive technology much quicker and more cost-effective, fully capitalizing on the current momentum within the lung cancer screening landscape. About Gustave Roussy Ranked as the leading European Cancer Centre and sixth in the world, Gustave Roussy is a centre with comprehensive expertise and is devoted entirely to patients suffering with cancer. The Institute is a founding member of the Paris Saclay Cancer Cluster. It is a source of diagnostic and therapeutic advances. It caters for almost 50,000 patients per year and its approach is one that integrates research, patient care and teaching. It is specialized in the treatment of rare cancers and complex tumors and it treats all cancers in patients of any age. Its care is personalized and combines the most advanced medical methods with an appreciation of the patient's human requirements. In addition to the quality of treatment offered, the physical, psychological and social aspects of the patient's life are respected. 4,100 professionals work on its two campuses: Villejuif and Chevilly-Larue.

Read More


Pictor announces funding round after successful launch in New Zealand and USA of SARS-CoV-2 Antibody Test

Pictor | December 05, 2022

Pictor, a global leader in immunodiagnostics announced a funding round to help accelerate pipeline product development projects along with market development activities within Australia/New Zealand, the US and Europe for its Human Health and Animal Health portfolios. This follows the recent successful launch of the PictArray™ SARS-CoV-2 IgG Antibody Test through Rako Science in New Zealand and key partners in the US. “The test better informs patients and doctors in determining whether the patient should be immunized or boosted,” said Pictor’s Chief Medical Officer Tadd Lazarus, MD. Pictor’s multiplex technology enables two key different approaches – testing for multiple diseases or testing for different stages/multiple markers of a disease, all within a single enzyme-linked immunosorbent assay test well. This can provide both greater sensitivity higher throughput and cost efficiencies. Within the Human Health space, Pictor’s current focus is expanding access to its highly accurate tests for COVID-19 antibodies and accelerating the development of its test for tropical fevers. Pictor has also leveraged its multiplex platform to develop an Animal Health business and is poised to launch two tests in Q2, 2023. The PictArray™ Mycoplasma bovis (M. bovis) and PictArray™ Johne’s Disease tests, developed with support from the Ministry for Primary Industries’ Sustainable Food and Fibre Futures fund, will enable more accurate and effective dairy and beef herd management both in New Zealand and internationally. “This funding round provides a potential opportunity for investors to realize a significant increase in value through the near-term commercialization of our current pipeline, along with acceleration of future product development projects.” In announcing the financing, Pictor CEO Howard Moore About Pictor Pictor is an in vitro diagnostics company that offers a patented multiplexed platform for highly accurate and efficient testing of complex and infectious diseases for human and animal health. PictArray™ multiplexed technology makes it possible to test multiple disease markers in a single test simultaneously — with higher sensitivity, faster throughput, and reduced turn-around time. The company’s lead product, the PictArray™ SARS-CoV-2 IgG ELISA Kit, enables more informed clinical intervention to manage the threat of COVID-19. About Marko Bogoievski Known as a high-conviction investor, Marko Bogoievski served as the chief executive officer of New Zealand-based Morrison & Co before stepping-down in December 2021. His career saw him lead Morrison & Co to become a global leader in infrastructure investment, specifically focused on data, renewable energy and healthcare. In his thirteen-year tenure with Morrison & Co, Bogoievski led growth in funds under management to over US$20 billion

Read More


Scientists have used biology to create technology for thousands of years have become really good at it. However, sometimes it feels like the promise of bio-based fuels, materials, and medicines have fallen flat.My research is re-imagining how we tinker with biology, how we might "think outside the cell"! Breaking open bacteria and using their parts to do chemistry allows us to design, build, and test  biotechnologies in a fraction of the time it would take in living bacteria. Now we can imagine a world where all of our material items were made from biology!